Preparation method and application of polypeptide pharmaceutical preparation

By using complexing agents, buffering systems and antioxidants in polypeptide vaccine preparations, the interference of active ingredients and chemical stability problems have been solved, and the stability and safety of polypeptide vaccines have been improved, reducing storage temperature requirements and improving R&D Efficiency and safety.

CN119055754APending Publication Date: 2024-12-03SHENZHEN JIANXIANG BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310645196.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Due to the mutual interference between active ingredients and chemical stability problems, polypeptide vaccines have difficulty in formulating and storage, requiring extremely low temperature conditions, and the chemical solvents used in the prior art are poor in safety.

Method used

Improve stability and safety among components by adding complexing agents (such as EDTA, citric acid), buffer systems (such as phosphate, succinic acid) and antioxidants (such as methionine, sodium sulfite) to polypeptide vaccine preparations to improve the stability and safety of components reduces storage temperature requirements.

Benefits of technology

The stability of the peptide vaccine has been improved, the storage temperature has been reduced to 5±3℃, the safety and R&D efficiency of the preparation have been improved, and the cost has been reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention discloses a preparation method of a polypeptide pharmaceutical preparation, which is mainly characterized in that a complexing agent, a buffer system and an antioxidant are added into a preparation formula consisting of different polypeptide active components, the stability of the polypeptide pharmaceutical preparation is improved, and the preparation method is used for preparing a multi-component polypeptide vaccine. The polypeptide vaccine can be stably stored at 5 + / -3 DEG C.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of polypeptide pharmaceutical compositions and is used for preparing stable polypeptide vaccines. Technical Background

[0002] Peptide vaccines are vaccines prepared by chemical synthesis technology according to the amino acid sequence of a known or predicted antigen epitope in the pathogen antigen gene. Peptides, as immunogens that cause effector cell immune responses in vivo, have become a new type of vaccine. Peptide vaccines have antiviral, antitumor, antibacterial, and anti-parasitic functions. Since peptide vaccines are completely synthetic, there is no problem of toxicity recovery or incomplete inactivation. They have the advantages of low cost, safety, strong specificity, easy storage and application, and are increasingly valued by the industry. From the progress of global peptide vaccines, typical peptide vaccines currently include hepatitis C virus peptide vaccines, influenza virus and HIV-1 peptide vaccines, tumor peptide vaccines, etc. Compared with small molecule chemical drugs, peptide vaccine drugs have the characteristics of poor stability and easy enzymatic hydrolysis. In the process of formulation process development, attention should be paid to the chemical and physical stability of peptide drugs.

[0003] Chinese patent CN115920018A discloses a tumor polypeptide vaccine for treating breast cancer and its preparation method. After mixing 8 polypeptides of equal mass together, PBS buffer is used to prepare the polypeptide mixture for preparing polypeptide vaccine to a concentration of 15 mg / ml. Chinese patent CN111558035A discloses a preparation method and application of polypeptide vaccine. The preparation method uses a solvent that is less destructive to polypeptides, prevents side chain oxidation, and can dissolve polypeptides, that is, the physiological saline containing DMSO and the DMSO mixture as solvents to dissolve the polypeptide active components and prepare polypeptide vaccines. The prepared polypeptide concentration needs to be stored at -80°C.

[0004] The problems with the existing technology are: on the one hand, polypeptide vaccines contain different active ingredients. Since multiple vaccine active ingredients may interfere with each other and are incompatible, the existing technology uses chemical solvents and no injection-grade materials, which results in poor safety. This poses great challenges to the formulation and preparation technology of the vaccine; on the other hand, due to the special molecular structure of polypeptides, especially when containing special amino acids such as disulfide bonds, the chemical stability of polypeptide vaccine preparations is greatly affected and often needs to be stored at extremely low temperatures. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a method for preparing a polypeptide pharmaceutical preparation, which can be used to prepare different polypeptide vaccines, so as to continuously improve the research and development efficiency of polypeptide vaccines, reduce research and development costs, improve safety, and bring new hope to patients with diseases around the world.

[0006] In order to overcome the above problems in the prior art, the present invention provides a method for preparing a polypeptide pharmaceutical preparation, which mainly involves adding a chelating agent, a buffer system, and an antioxidant to a preparation formula composed of different polypeptide active ingredients.

[0007] In some embodiments, the complexing agent is selected from EDTA, citric acid, tartaric acid.

[0008] In some embodiments, the buffer system is selected from phosphate, citrate, carbonate, acetate, succinate.

[0009] In some embodiments, the antioxidant is selected from methionine, cysteine, and sodium sulfite.

[0010] Preferably, the complexing agent is selected from EDTA.

[0011] Preferably, the concentration of EDTA is 0.2-1.0 mg / mL.

[0012] Preferably, the buffer system is selected from succinic acid.

[0013] Preferably, the concentration of succinic acid is 0.5 to 2.0 mg / mL.

[0014] Preferably, the antioxidant is selected from methionine.

[0015] Preferably, the mass ratio of methionine to the single polypeptide active ingredient is 10:1 to 20:1.

[0016] In some embodiments, the number of the polypeptide active components is 2 to 4.

[0017] In some embodiments, the pH value of the polypeptide preparation is between 5.5 and 6.5.

[0018] Preferably, the pH value of the polypeptide preparation is 6.0.

[0019] The method is used in the preparation of polypeptide vaccines.

[0020] Preferably, the polypeptide vaccine is a polypeptide drug containing a disulfide bond.

[0021] The present invention provides a method for preparing a multi-component vaccine preparation, which solves the problem that multiple vaccine active ingredients interfere with each other and are incompatible, and the technical problem that polypeptide vaccine preparations often need to be stored at extremely low temperatures. Through the method of the present invention, the antioxidant in the excipient can play an antioxidant role, the chelating agent and the buffer system can stabilize the components, and the storage temperature of the polypeptide preparation can be 5±3°C. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Process flow chart

[0023] Figure 2 HPLC spectrum of a two-component peptide vaccine preparation

[0024] Figure 3 HPLC spectrum of a 2-component peptide vaccine preparation after 6 months of storage DETAILED DESCRIPTION

[0025] The specific implementation modes of the present invention are described in detail below in conjunction with the accompanying drawings. The described embodiments are only for illustration and explanation of the present invention and do not constitute the sole limitation of the present invention.

[0026] Example 1: Preparation of a two-component polypeptide vaccine

[0027] Weigh about 150ml of injection water cooled to room temperature (20±10℃), add it to the liquid preparation container, and start stirring. Add the prescribed amount of succinic acid 200mg, EDTA 100mg, and methionine 100mg in sequence and stir until completely dissolved. Then weigh the prescribed amount of polypeptide 1 raw material 10mg and polypeptide 2 raw material 10mg in sequence, take a small amount of the above excipient solution and pre-dissolve it into the liquid preparation container, and rinse the container with room temperature injection water in small amounts several times; take a sample to measure the pH value (should be 6.0±0.3), then add the remaining injection water, make up to 200ml, stir for 5min, and mix evenly. Take a sample before filtering, measure the properties, pH, content, and related substances. After preparation, pass through two-stage sterilization grade 0.22μm, PVDF microporous filter element, sterilize and filter to the drug receiving bag, and record the start time. During sterilization filtration, the pressure upstream of the sterilization filter is ≤0.2Mpa. After filling and freeze-drying, a two-component polypeptide vaccine preparation was obtained. The process flow chart is shown in Appendix 1, and the HPLC spectrum is shown in Appendix 2. The finished product was stored at 5±3°C. The HPLC spectrum after 6 months is shown in Appendix 3. After 6 months, there was no significant change in the content of polypeptide 1 and polypeptide 2, and no obvious increase in impurities, which met the quality standards.

[0028] Table 1

[0029]

[0030] Example 2: Preparation of a 4-component polypeptide vaccine

[0031] Take 120ml of water for injection (temperature is 22±4℃), add 200mg of EDTA, 100mg of disodium hydrogen phosphate, 200mg of sodium sulfite, and adjust the pH to 6.0±0.2 with 1M sodium hydroxide solution; then fill the solution with nitrogen for 20min to ensure that the oxygen content in the solution is ≤3ppm, otherwise continue to fill with nitrogen until qualified; set aside. Add the auxiliary material solution to the liquid preparation container, take a small amount of auxiliary material solution, and pre-dissolve the raw materials respectively. Then add 10mg of active polypeptide A raw material, 10mg of B raw material, 10mg of C raw material, 10mg of D raw material and other mass ratios to the above buffer solution in turn. Stir for more than 10min after each addition. After the raw materials are completely dissolved, adjust the pH to 6.0±0.2 with sodium hydroxide solution, use water for injection to make up to 200ml, and continue to fill with nitrogen to ensure that the oxygen content in the solution is ≤3ppm. Sterilization and filtration: The drug solution is protected by nitrogen, powered by a peristaltic pump, and filtered through a two-stage 0.22μm PVDF filter element (Cobite filter element); it is filled at 2-8°C and freeze-dried using low-temperature freeze-drying technology to obtain a four-component polypeptide vaccine preparation. The finished product is stored at 5°C±3°C and has good stability. The content and related substances of the newly produced sample and the sample after 12 months of storage are compared as shown in the following table. The content is stable, there is no obvious increase in impurities, and all meet the quality standards.

[0032] Table 2

[0033]

[0034]

[0035] Example 3: Preparation of 4-component polypeptide vaccine 2

[0036] Take 2 portions of 80ml water for injection (temperature 22±4℃) and place them in containers. Fill the first solution with nitrogen and add 200mg methionine, stir and dissolve it thoroughly, then add 20mg of polypeptide A raw material, stir until it is completely dissolved and seal it for later use, and mark it as solution 1. Add 14.2mg succinic acid, 140mg propylene glycol and EDTA to the second solution and dissolve them thoroughly, then start the cold water circulation equipment to reduce the temperature of the liquid to 2-8℃, then add 20mg of polypeptide B raw material, 20mg of C raw material, and 20mg of D raw material in turn, stir until they are completely dissolved, after the raw materials are dissolved, introduce nitrogen until the oxygen content of the solution is lower than 3PPM, and mark it as solution 2. Add 20ml of cooled water for injection to the small liquid preparation tank, turn on the agitator of the liquid preparation tank, slowly add solution 2 and then slowly add solution 1, control the liquid to minimize bubbles, after complete addition, continue to add water for injection to 200ml, and measure the content and pH. Sterilization and filtration: The drug solution is protected by nitrogen, powered by a peristaltic pump, and filtered through a two-stage 0.22μm PVDF filter element (Cobite filter element); it is filled at 2-8°C and freeze-dried using low-temperature freeze-drying technology to obtain a four-component polypeptide vaccine preparation. The finished product is stored at 5°C±3°C and has good stability. The content and related substances of the newly produced sample and the sample after 24 months of storage are compared as shown in the following table. The content is stable, and there is no obvious increase in impurities, which all meet the quality standards.

[0037] Table 3

[0038]

Claims

1. A method for preparing a polypeptide pharmaceutical preparation, characterized in that: It is mainly achieved by adding chelating agents, buffer systems and antioxidants to the formulation composed of different polypeptide active ingredients.

2. The preparation method according to claim 1, characterized in that: The complexing agent is selected from EDTA, citric acid and tartaric acid.

3. The preparation method according to claim 1, characterized in that: The buffer system is selected from phosphate, citrate, carbonate, acetate, and succinic acid.

4. The preparation method according to claim 1, characterized in that: The antioxidant is selected from methionine, cysteine ​​and sodium sulfite.

5. The preparation method according to claim 2, wherein the complexing agent is preferably EDTA.

6. The preparation method according to claim 5, wherein the concentration of EDTA is 0.2 to 1.0 mg / mL.

7. The preparation method according to claim 3, characterized in that: The buffer system is preferably succinic acid.

8. The preparation method according to claim 7, wherein the concentration of succinic acid is 0.5 to 2.0 mg / mL.

9. The preparation method according to claim 4, characterized in that The antioxidant is selected from methionine.

10. The preparation method according to claim 9, wherein the mass ratio of methionine to the single polypeptide active ingredient is 10:1 to 20:

1.

11. The preparation method according to claim 1, characterized in that: The number of the polypeptide active ingredients is 2 to 4.

12. The preparation method according to claim 1, characterized in that: The pH value of the peptide preparation is between 5.5 and 6.

5.

13. Use of the method according to any one of claims 1 to 12 in the preparation of a polypeptide vaccine.

14. The use according to claim 13, characterized in that The polypeptide vaccine is a polypeptide drug containing a disulfide bond.